#Market News January 26, 2018 / 8:37 PM / in 4 minutes BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model Reuters Staff 1 Min Read 
Jan 26 (Reuters) - Verastem Inc: 
* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL 
* VERASTEM - DATA SUPPORT EXPLORATION OF DUVELISIB IN COMBINATION WITH ANTI-PD-1/PD-L1 OR CO-STIMULATORY ANTIBODIES IN PATIENTS WITH B CELL MALIGNANCIES 
* VERASTEM INC - DUVELISIB IS BEING STUDIED IN OTHER HEMATOLOGIC MALIGNANCIES INCLUDING PERIPHERAL T CELL LYMPHOMA 
* VERASTEM INC - PLANS TO SUBMIT NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR DUVELISIBâ€‹ DURING Q1 2018 
* VERASTEM INC - DUVELISIB ALONE, ANTI-PD-1 ALONE AND ANTI-OX40 ALONE EACH INDUCED TUMOR GROWTH DELAY 
* VERASTEM INC - WHEN DUVELISIB AND ANTI-PD-1 WERE COMBINED, STRONG ANTI-TUMOR SYNERGY WAS OBSERVED Source text for Eikon: Further company coverage: